Patient outcomes using the European label for dabigatran

Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation

(2013) Torben Bjerregaard Larsen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation

(2013) John W. Eikelboom et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dabigatran and Postmarketing Reports of Bleeding

(2013) Mary Ross Southworth et al.   NEW ENGLAND JOURNAL OF MEDICINE

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPEAN HEART JOURNAL

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

(2012) Gregory Y. H. Lip et al.   THROMBOSIS AND HAEMOSTASIS

Prognosis and Guideline-Adherent Antithrombotic Treatment in Patients With Atrial Fibrillation and Atrial Flutter

(2011) Laurent Gorin et al.   CHEST

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

(2011) K. A. A. Fox et al.   EUROPEAN HEART JOURNAL

Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran

(2011) B. Nhi Beasley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation

(2010) Michael D. Ezekowitz et al.   CIRCULATION

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPEAN HEART JOURNAL

Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation

(2010) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

(2010) Hans-Christoph Diener et al.   LANCET NEUROLOGY

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE